Biogen | BIIB - Operating Profit


Biogen reported $659.6M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 4.58B 1.13B Sep/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025